We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
19 September 2022
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases is to be sold to Genfit SA (NASDAQ: GNFT). With this acquisition Genfit seeks to expand it pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE). Deal terms include a payment of CHF 40 million, an aggregate of CHF 65 million of potential additional payments contingent on successful clinical and regulatory milestones, and one-third of the net proceeds from the potential sale of a Priority Review Voucher, if awarded by the FDA . VISCHER AG is assisting Versantis with Mark Fitzpatrick as CEO, Vincent Forster as CSO and Meriam Kabbaj as COO. The team is led by Matthias Staehelin with Christian Wyss, Vincent Reardon and Pauline Pfirter (all Corporate/M&A) as well as Christoph Niederer and Veysel Oruclar (both Tax).
Categories: Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Startup Desk
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law
Attorney at Law, Swiss Certified Tax Expert
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...